Genelux Corporation (GNLX) Dividend History

Company News

• Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

  Genelux Corporation, a late clinical-stage immuno-oncology company, announced that its President, Chairman and CEO will discuss the company's clinical-stage programs, recent announcements, and upcoming milestones at the H.C. Wainwright Global Healthcare Conference.

  GlobeNewswire Inc.
• Unveiling 4 Analyst Insights On Genelux

  Genelux (NASDAQ:GNLX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $29.75, a high estimate of $32.00, and a low estimate of $25.00. This current average represents a 8.46% decrease from the previous average price target of $32.50. Exploring Analyst Ratings: An In-Depth Overview The standing of Genelux among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Bruce Jackson Benchmark Lowers Speculative Buy $25.00 $30.00 Emily Bodnar HC Wainwright & Co. Maintains Buy $32.00 - Bruce Jackson Benchmark Maintains Speculative Buy $30.00 - Emily Bodnar HC Wainwright & Co. Lowers Buy $32.00 $35.00 Key Insights: Action Taken: In response to ...Full story available on Benzinga.com

  Benzinga
• Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround

  Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  Zacks Investment Research
• Why Shares of Genelux Climbed This Week

  The company's shares rose on signs it might be getting closer to its first biologics license application.

  The Motley Fool